# US 2003/0225053 A1 · Compounds useful in treating cytokine mediated diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0225053 A1
- Document ID: US20030225053A1
- Status: Published application
- Kind: A1
- Application number: 10/410,688
- Filed: 2003-04-10
- Published: 2003-12-04
- Earliest claimed: 2002-04-11
- Assignees: Boehringer Ingelheim Pharmaceuticals, Inc.
- Inventors: Donghong Amy Gao; Daniel R. Goldberg; Abdelhakim Hammach; Ming-Hong Hao; Victor Marc Kamhi; Neil Moss; Kevin Chungeng Qian; Gregory Paul Roth; Christopher Ronald Sarko; Alan David Swinamer; Zhaoming Xiong
- Web page: https://patentgrep.com/patent/US20030225053A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 311/08: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07D 209/42: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 307/85: attached in position 2
- C07D 333/70: attached in position 2
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Disclosed are amide compounds of formula(I): 1 wherein Ar1, Q, Y and R3-R6 of formula(I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

## Claims

### Claim 1

A compound of the formula (I):
60
Q is a nitrogen or CRpRv;
Y is CRpRv, CRp═CRv, O, N—Rx or S(O)n;
wherein Rp, Rv and Rx are hydrogen or C1-5 alkyl;
Ar1 is carbocycle optionally substituted with one R1, and wherein Ar1 is independently substituted with two R2 groups;
R1 is NO2, —N(Ra)2 or the formula:
J—M1—M2— wherein:
one of M1 and M2 is S(O)m and the other is N—Ra,
J is chosen from C1-10 alkyl and carbocycle each optionally substituted by Rb;
R2 is independently chosen from C1-6 alkyl or C3-7 cycloalkyl which may optionally be partially or fully halogenated, C1-4 acyl, aroyl, C1-4 alkoxy, which may optionally be partially or fully halogenated, halogen, C1-6 alkoxycarbonyl, carbocyclesulfonyl and —SO2—CF3;
each R4 and R5 are independently chosen from hydrogen, C1-6 alkyl and halogen;
each R3 and R6 are independently hydrogen, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, C2-5 akynyl, C1-5 alkoxy, C1-5 alkylthio, amino, C1-5 alkylamino, C1-5 dialkylamino, C1-5 acyl, C1-5 alkoxycarbonyl, C1-5 acyloxy, C1-5 acylamino, each of the aforementioned are optionally partially or fully halogenated, C1-5 alkylsulphonylamino, hydroxy, halogen, nitrile, carbocycleC0-6 alkyl, heteroarylC0-6alkyl, heterocyclylC0-6alkyl each carbocycle, heteraryl or heterocyclyl optionally substituted with Rc, or one of R3 or R6 is the formulas (II) or (III):
61
wherein Z is chosen from aryl, C3-7 cycloalkyl, cyclohexanone, heterocycle chosen from pyrrolidinyl, pyrrolinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, dioxalanyl, piperidinyl, piperazinyl, tetrahydrofuranyl, 1-oxo-λ4-thiomorpholinyl, 13-oxa-11-aza-tricyclo[7.3.1.0-2,7]trideca-2,4,6-triene, tetrahydropyranyl, 2-oxo-2H-pyranyl, tetrahydrofuranyl, 1,3-dioxolanone, 1,3-dioxanone, 1,4-dioxanyl, 8-oxa-3-aza-bicyclo[3.2.1]octanyl, 2-oxa-5-aza-bicyclo[2.2.1]heptanyl, 2-thia-5-aza-bicyclo[2.2.1]heptanyl, piperidinonyl, tetrahydropyrimidonyl, pentamethylene sulfide, pentamethylene sulfoxide, pentamethylene sulfone, tetramethylene sulfide, tetramethylene sulfoxide and tetramethylene sulfone or heteroaryl chosen from aziridinyl, thienyl, furanyl, isoxazolyl, oxazolyl, thiazolyl, thiadiazolyl, tetrazolyl, pyrazolyl, pyrrolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyranyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzothienyl, quinolinyl, quinazolinyl, naphthyridinyl, indazolyl, triazolyl, pyrazolo[3,4-b]pyrimidinyl, purinyl, pyrrolo[2,3-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, tubercidinyl, oxazo[4,5-b]pyridinyl and imidazo[4,5-b]pyridinyl, each optionally substituted by one to three Rd;
Re and Rf are independently chosen from hydrogen, C1-5 alkyl and Z, the Z is optionally substituted by one to three Rd;
Ra, Rb and Rc are each independently chosen from hydrogen, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, carbocycle, C1-5 alkoxy, C1-5 alkylthio, amino, C1-5 alkylamino, C1-5 dialkylamino, C1-5 acyl, C1-5 alkoxycarbonyl, C1-5 acyloxy, C1-5 acylamino, each of the aforementioned are optionally partially or fully halogenated, or Ra, Rb and Rc are chosen from C1-5 alkylsulphonylamino, hydroxy, halogen, nitro and nitrile;
Rd is as defined for Ra, Rb and Rc above, aminoacyl or amino wherein for each the N atom is mono- or di-substituted by C1-4 alkyl, aminoC1-3 acyl, arylC0-3 alkyl, C3-7cycloalkylC0-3 alkyl, heteroarylC0-3 alkyl, heterocyclylC0-3 alkyl, C1-5alkylC1-5alkoxy or C1-4alkylamino-mono-or-di-substituted by C1-3alkyl, or Rd is
62
wherein a and t are independently 1, 2 or 3 and L is a heteroatom chosen from N, O and S, or Rd is Ar3—C(O)— and Ar3—S(O)m— wherein is Ar3 is chosen from carbocycle, heterocyclyl and heteroaryl, each carbocycle, heterocyclyl and heteroaryl in this paragraph for Rd or Ar3 are optionally substituted by one to two C1-5 alkyl, C1-5 alkoxy, C1-5 alkoxycarbonyl or halogen;
n is 0,1 or 2 and
m is 0, 1 or 2;
or the pharmaceutically acceptable acids and salts or isomers thereof;
with the proviso that:
if R1 is not present then one of R3 or R6 must be the formulas (II) or (III), or if one of R3 or R6 is nitro then R1 must be present.

### Claim 2 (depends on 1)

The compound according to claim 1 and wherein
Q is CH2;
Y is CH═CH, N—Rx or S(O)n;
J is chosen from C1-10 alkyl, aryl or C3-7 cycloalkyl each optionally substituted by Rb;
R2 is independently chosen from C1-6 alkyl which may optionally be partially or fully halogenated, acetyl, aroyl, C1-4 alkoxy, which may optionally be partially or fully halogenated, halogen, methoxycarbonyl, phenylsulfonyl and —SO2—CF3;
each R4 and R5 are independently chosen from hydrogen, C1-C4 alkyl, F, Cl and Br;
each R3 and R6 are independently hydrogen, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, C3-8 cycloalkyl, C1-5 alkoxy, C1-5 alkylthio, amino, C1-5 alkylamino, C1-5 dialkylamino, C1-5 acyl, C1-5 alkoxycarbonyl, C1-5 acyloxy, C1-5 acylamino, each of the aforementioned are optionally partially or fully halogenated, C1-5 alkylsulphonylamino, hydroxy, halogen, trifluoromethyl, nitrile, arylC0-6 alkyl, heteroarylC0-6 alkyl wherein the heteroaryl is chosen from thienyl, furanyl, isoxazolyl, oxazolyl, thiazolyl, thiadiazolyl, tetrazolyl, pyrazolyl, pyrrolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyranyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzothienyl, quinolinyl, quinazolinyl and indazolyl, cycloalkylC0-6 alkyl or heterocyclylC0-6 alkyl wherein the heterocyclyl is chosen from pyrrolidinyl, pyrrolinyl, morpholinyl, thiomorpholinyl, dioxalanyl, piperidinyl, piperazinyl, aziridinyl and tetrahydrofuranyl, each of the above R3 or R6 optionally substituted with Rc, or one of R3 or R6 is the formulas (II) or (III):
63
wherein Z is chosen from aryl, C3-7 cycloalkyl, heterocycle chosen from pyrrolidinyl, pyrrolinyl, morpholinyl, thiomorpholinyl, dioxalanyl, piperidinyl, piperazinyl, aziridinyl and tetrahydrofuranyl or heteroaryl chosen from thienyl, furanyl, isoxazolyl, oxazolyl, thiazolyl, thiadiazolyl, tetrazolyl, pyrazolyl, pyrrolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyranyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzothienyl, quinolinyl, quinazolinyl and indazolyl, each Z optionally substituted by one to two Rd;
Ra, Rb and Rc are each independently chosen from hydrogen, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, C3-8 cycloalkylC0-2 alkyl, aryl, C1-5 alkoxy, C1-5 alkylthio, amino, C1-5 alkylamino, C1-5 dialkylamino, C1-5 acyl, C1-5 alkoxycarbonyl, C1-5 acyloxy, C1-5 acylamino, or Ra, Rb and Rc are chosen from C1-5 sulphonylamino, hydroxy, halogen, trifluoromethyl, nitro and nitrile;
Rd is as defined for Ra, Rb and Rc above, aminoacyl or amino wherein for each the N atom is mono- or di-substituted by C1-4 alkyl, aminoC1-3 acyl, arylC0-3 alkyl, C3-7 cycloalkylC0-3 alkyl, heteroarylC0-3 alkyl, heterocyclylC0-3 alkyl, C1-5alkylC1-5alkoxy or C1-4alkylamino-mono-or-di-substituted by C1-3alkyl, Ar3—C(O)— and Ar3—S(O)m— wherein Ar3 is heterocyclyl, each aryl, heterocyclyl and heteroaryl in this paragraph for Rd or Ar3 are optionally substituted by one to two C1-5 alkyl, C1-5 alkoxy, C1-5 alkoxycarbonyl or halogen; and
n is 0.

### Claim 3 (depends on 2)

The compound according to claim 2 and wherein
Ar1 is chosen from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, phenyl, naphthyl, tetrahydronaphthyl, indanyl and indenyl, each Ar1 is substituted with one R1, and independently substituted with two R2 groups;
R1 is NO2, NH2, C1-3acylNH— or the formula:
J—S(O)m—N(Ra)—;
J is C1-10 alkyl;
R2 is independently chosen from C1-6 alkyl which may optionally be partially or fully halogenated and C1-3 alkoxy, which may optionally be partially or fully halogenated;
each R3 and R6 are independently hydrogen, C1-5 alkyl, amino, C1-5 alkylamino, C1-5 dialkylamino, C1-5 acylamino, each of the aforementioned are optionally partially or fully halogenated, C1-5 alkylsulphonylamino, halogen, nitro, nitrile, or one of R3 or R6 is the formulas (II) or (III):
64
wherein Z is chosen from phenyl, C3-7 cycloalkyl, morpholinyl, thiomorpholinyl, thienyl, furanyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinoxalinyl, quinolinyl, and quinazolinyl, each Z optionally substituted by one to two Rd, Re and Rf are independently hydrogen or C1-3 alkyl, and
m is 2.

### Claim 4 (depends on 3)

The compound according to claim 3 and wherein
Y is CH═CH, N—CH3, N—CH2—CH3, N—CH2CH2CH3 or S;
Ar1 is
65
R1 is the formula:
J—S(O)2—NH—;
J is C1-5 alkyl;
R2 is independently chosen from C1-5 alkyl which may optionally be partially or fully halogenated and C1-2 alkoxy, which may optionally be partially or fully halogenated;
each R4 and R5 are hydrogen;
each R3 and R6 are independently hydrogen, C1-5 acylamino optionally partially or fully halogenated, halogen, nitro, or one of R3 or R6 is the formulas (II) or (III):
66
wherein Z is chosen from phenyl, cyclopropyl, morpholinyl, furanyl, pyridinyl, pyrimidinyl, pyrazinyl and quinoxalinyl, each Z is optionally substituted by one to two Rd; and
Rd is chosen from C1-5 alkyl, C3-6 cycloalkylC0-2 alkyl, aryl, C1-5 alkoxy, amino, C1-5 alkylamino, C1-5 dialkylamino, C1-5 acylamino, halogen, trifluoromethyl, nitro, nitrile, aminoacyl or amino wherein for each the N atom is mono- or di-substituted by C1-3 alkyl, aminoC1-2 acyl, phenylC0-3 alkyl, C3-6cycloalkylC0-2 alkyl, C1-5alkylC1-5alkoxy or C1-3 alkylN(C1-3 alkyl)2, Ar3—C(O)— and Ar3—S(O)m— wherein Ar3 is heterocyclyl chosen from pyrrolidinyl, pyrrolinyl, morpholinyl, thiomorpholinyl, dioxalanyl, piperidinyl, piperazinyl, aziridinyl and tetrahydrofuranyl, each phenyl, heterocyclyl and heteroaryl in this paragraph for Rd or Ar3 are optionally substituted by one to two C1-5 alkyl, C1-5 alkoxy, C1-5 alkoxycarbonyl or halogen.

### Claim 5 (depends on 4)

The compound according to claim 4 and wherein:
Y is N—CH3 or S;
J is C1-3 alkyl;
R2 is independently chosen from C1-5 alkyl which may optionally be partially or fully halogenated and C1-2 alkoxy, which may optionally be partially or fully halogenated;
each R3 and R6 are independently hydrogen, C1-5 acylamino optionally partially or fully halogenated, halogen, nitro, or one of R3 or R6 is the formula (II)
67
wherein Z is chosen from phenyl, cyclopropyl, morpholinyl, furanyl, pyridinyl, pyrimidinyl, pyrazinyl and quinoxalinyl, each Z optionally substituted by one to two Rd; and
Rd is chosen from C1-3 alkyl, methoxy, amino, F, Cl, nitro, aminoacyl or amino wherein for each the N atom is mono- or di-substituted by C1-3alkyl, amino C1acyl, benzyl, cyclopropyl, cyclopropylmethyl, cyclohexylmethyl, C1-3alkylC1-3alkoxy or C1-3 alkylN(C1-2 alkyl)2, Ar3—C(O)— and Ar3—S(O)m— wherein Ar3 is heterocyclyl chosen from morpholinyl and piperazinyl, each phenyl group and heterocyclyl in this paragraph for Rd or Ar3 are optionally substituted by one to two C1-3 alkyl, C1-3 alkoxy, C1-5 alkoxycarbonyl or halogen.

### Claim 6 (depends on 5)

The compound according to claim 5 and wherein
Y is N—CH3;
Ar1 is
68
and
Rd is morpholinyl-C(O)—.

### Claim 7 (depends on 5)

The compound according to claim 5 and wherein
Y is S;
Ar1 is
69
Rd is chosen from methyl, methoxy, amino, F, Cl, nitro, CH3NHCO—, (CH3)2NCO—, CH3NH—, (CH3)2N(CH2)3NH—, cyclopropyl-NH—, cyclopropylmethyl-NH—, cyclohexylmethyl-NH—, CH3OCH2CH2NH—, (CH3)2NCO—NH—, and Ar3—S(O)m— wherein Ar3 is morpholinyl optionally substituted by C1-5 alkoxycarbonyl.

### Claim 8 (depends on 4)

The compound according to claim 4 and wherein
one of R3 or R6 is the formula (III):
70
Re and Rf are chosen from methyl and ethyl, and
Ar1 is
71

### Claim 9 (depends on 2)

The compound according to claim 2 and wherein
R1 is not present;
Y is S or N—C1-5 alkyl;
Ar1 is chosen from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, phenyl, naphthyl, tetrahydronaphthyl, indanyl and indenyl, each Ar1 is independently substituted with two R2 groups;
R2 is independently chosen from C3-6 alkyl which may optionally be partially or fully halogenated, C1-4 alkoxy, which may optionally be partially or fully halogenated;
one of R3 or R6 is the formula (II):
72
wherein Z is chosen from phenyl, C3-7 cycloalkyl, morpholinyl, thiomorpholinyl, thienyl, furanyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinoxalinyl, quinolinyl, and quinazolinyl.

### Claim 10 (depends on 9)

The compound according to claim 9 and wherein
Y is S or N—CH3;
Ar1 is
73
R2 is independently chosen from C3-5 alkyl which may optionally be partially or fully halogenated and C1-4 alkoxy, which may optionally be partially or fully halogenated;
each R4 and R5 are hydrogen;
Z is chosen from phenyl, cyclopropyl, morpholinyl, furanyl, pyridinyl, pyrimidinyl, pyrazinyl and quinoxalinyl.

### Claim 11 (depends on 10)

The compound according to claim 10 and wherein
R2 is independently chosen from C4-5 alkyl which may optionally be partially or fully halogenated and C1-3 alkoxy, which may optionally be partially or fully halogenated;
Z is chosen from phenyl, cyclopropyl, morpholinyl, furanyl, pyridinyl, pyrimidinyl, pyrazinyl and quinoxalinyl.

### Claim 12 (depends on 11)

The compound according to claim 11 and wherein Z is pyridinyl.

### Claim 13

A compound chosen from
74 75 76 77 78 79 80 81 82 83 84 85
or the pharmaceutically acceptable acids and salts or isomers thereof.

### Claim 14

A compound chosen from
86 87
or the pharmaceutically acceptable acids and salts or isomer thereof.

### Claim 15

A compound chosen from
88
or the pharmaceutically acceptable acids and salts or isomers thereof.

### Claim 16 (depends on 1)

A process of making a compound of the formula(I) according to claim 1 wherein Q is a carbon atom and R6 is
89
said process comprising:
1) coupling an amine II bearing Ar1 with nitro carboxylic acid III using suitable coupling conditions in a suitable solvent to produce compound IV:
90
2) reducing IV to the amine V under suitable reducing conditions, followed by coupling the resulting amine V with a carboxylic acid bearing Z under suitable coupling conditions in a suitable solvent:
91
and subsequently isolating the product compound of the formula (I).

### Claim 17 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to claim 1 and one or more pharmaceutically acceptable carriers and/or adjuvants.

### Claim 18 (depends on 1)

A method of treating a cytokine mediated disease or condition which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound according to claim 1.

### Claim 19 (depends on 18)

The method according to claim 18 wherein cytokine mediated disease or condition is selected from rheumatoid arthritis, inflammatory bowel disease, septic shock, osteoarthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, Guillain-Barre syndrome, psoriasis, graft versus host disease, systemic lupus erythematosus, restenosis following percutaneous transluminal coronary angioplasty, diabetes, toxic shock syndrome, Alzheimer's disease, acute and chronic pain, contact dermatitis, atherosclerosis, traumatic arthritis, glomerulonephritis, reperfusion injury, sepsis, bone resorption diseases, chronic obstructive pulmonary disease, congestive heart failure, asthma, stroke, myocardial infarction, thermal injury, adult respiratory distress syndrome (ARDS), multiple organ injury secondary to trauma, dermatoses with acute inflammatory components, acute purulent meningitis, necrotizing enterocolitis and syndromes associated with hemodialysis, leukopherisis and granulocyte transfusion.

### Claim 20 (depends on 19)

The method according to claim 19 wherein the disease is selected from rheumatoid arthritis, osteoarthritis, Crohn's disease, psoriasis, ulcerative colitis, osteoporosis, chronic obstructive pulmonary disease, restenosis following percutaneous transluminal coronary angioplasty and congestive heart failure.
